252 filings
20-F
2023 FY
MDWD
MediWound Ltd
Annual report (foreign)
21 Mar 24
8:08am
6-K
MDWD
MediWound Ltd
21 Mar 24
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company
7:05am
6-K
MDWD
MediWound Ltd
12 Feb 24
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
7:05am
6-K
MDWD
MediWound Ltd
9 Jan 24
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
7:05am
6-K
MDWD
MediWound Ltd
8 Jan 24
Current report (foreign)
7:00am
6-K
jfsaw9
28 Dec 23
MediWound Secures Additional U.S. Department of Defense Funding to
7:05am
6-K
clfrpnd6s217
15 Dec 23
Current report (foreign)
4:05pm
6-K
xtxjl
21 Nov 23
MediWound Reports Third Quarter 2023 Financial Results and Provides
7:05am
6-K
dest8 ff8rbdc
21 Nov 23
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer
7:03am
6-K
9xs8837pqt
13 Nov 23
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
7:05am
6-K
qdefuq04r0ok36gbead
26 Sep 23
MediWound Secures Additional U.S. Department of Defense Funding to
4:05pm
6-K
9owxzdbudmkxbtjj
21 Sep 23
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
6:05am
S-8
llr5uc6ct52
15 Aug 23
Registration of securities for employees
4:14pm
6-K
hfds8la1srao9nu0ag
15 Aug 23
MediWound Reports Second Quarter 2023 Financial Results and Provides
4:10pm
6-K
220 czn6fmxoy7
15 Aug 23
Current report (foreign)
4:01pm
6-K
4ok0tqkrg88ih5
2 Aug 23
Current report (foreign)
8:00am
6-K
b3kstqr
17 Jul 23
Current report (foreign)
4:01pm
6-K
ivlj5h0pvfsu1h stzhy
10 Jul 23
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005
7:35am
6-K
btdr63l7iy4a7
3 Jul 23
MediWound Receives Positive Scientific Advice from European Medicine
7:05am
6-K
6z688tw33 dx
31 May 23
Current report (foreign)
4:10pm